CMPX insider trading
HealthcareCompass Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Compass Therapeutics, Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies. It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody for angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.
Company website: www.compasstherapeutics.com
CMPX insider activity at a glance
FilingIQ has scored 85 insider transactions for CMPX since Jun 25, 2021. The most recent filing in our index is dated Apr 29, 2026.
Across the full history, 44 open-market purchases
and 7 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on CMPX insider trades is 56.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest CMPX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for CMPX?
- FilingIQ tracks 85 Form 4 insider transactions for CMPX (Compass Therapeutics, Inc.), covering filings from Jun 25, 2021 onwards. 4 of those were filed in the last 90 days.
- Are CMPX insiders net buyers or net sellers?
- Across the full Form 4 history for CMPX, 44 transactions (52%) were open-market purchases and 7 (8%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does CMPX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is CMPX in?
- Compass Therapeutics, Inc. (CMPX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.14B.
Methodology & sources
Every CMPX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.